ES2163394T3 - Regiones serorreactivas situadas en las proteinas e1 y e2 de hpv16. - Google Patents

Regiones serorreactivas situadas en las proteinas e1 y e2 de hpv16.

Info

Publication number
ES2163394T3
ES2163394T3 ES92110430T ES92110430T ES2163394T3 ES 2163394 T3 ES2163394 T3 ES 2163394T3 ES 92110430 T ES92110430 T ES 92110430T ES 92110430 T ES92110430 T ES 92110430T ES 2163394 T3 ES2163394 T3 ES 2163394T3
Authority
ES
Spain
Prior art keywords
proteins
serrereactive
hpv16
seroactive
regions situated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92110430T
Other languages
English (en)
Inventor
Martin Muller
Lutz Gissmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Dade Behring Marburg GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dade Behring Marburg GmbH filed Critical Dade Behring Marburg GmbH
Application granted granted Critical
Publication of ES2163394T3 publication Critical patent/ES2163394T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)

Abstract

LA INVENCION SE REFIERE A PROTEINAS E1 Y E2 DE CAMPO SEROACTIVO DE LOS VIRUS PAPILOMAS HUMANOS (HPV) 16. ADEMAS LA INVENCION SE REFIERE A UNA VACUNA, QUE CONTIENE TAL PEPTIDO, QUE ABARCA LOS CAMPOS SEROACTIVOS. LA INVENCION ABARCA ASIMISMO COMPOSICIONES PARA MOTIVO DE DIAGNOSTICO, QUE CONTIENEN PEPTIDOS CON EL CAMPO SEROACTIVO.
ES92110430T 1991-07-18 1992-06-20 Regiones serorreactivas situadas en las proteinas e1 y e2 de hpv16. Expired - Lifetime ES2163394T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4123760A DE4123760C2 (de) 1991-07-18 1991-07-18 Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2

Publications (1)

Publication Number Publication Date
ES2163394T3 true ES2163394T3 (es) 2002-02-01

Family

ID=6436409

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92110430T Expired - Lifetime ES2163394T3 (es) 1991-07-18 1992-06-20 Regiones serorreactivas situadas en las proteinas e1 y e2 de hpv16.

Country Status (10)

Country Link
US (5) US5601973A (es)
EP (2) EP1136500A3 (es)
JP (2) JPH0867696A (es)
AT (1) ATE206434T1 (es)
AU (1) AU668094B2 (es)
CA (1) CA2074153C (es)
DE (2) DE4123760C2 (es)
DK (1) DK0523395T3 (es)
ES (1) ES2163394T3 (es)
PT (1) PT523395E (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4430821B2 (ja) * 1998-07-21 2010-03-10 ベーリンガー インゲルハイム （カナダ） リミテッド Ｅ１オリゴマー化に関係するパピローマウイルスｅ１ヘリカーゼの領域
GB9916363D0 (en) * 1999-07-13 1999-09-15 Univ Bristol Methods of suppressing cell growth
DK1301614T3 (da) * 2000-07-21 2007-04-02 Glaxo Group Ltd Codon-optimerede papillomavirus-sekvenser
GB0017990D0 (en) 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
CA2431500C (en) 2000-12-08 2016-06-07 Sjoerd Hendrikus Van Der Burg Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
US7027923B2 (en) * 2003-12-12 2006-04-11 Schlumberger Technology Corporation Method for determining sonde error for an induction or propagation tool with transverse or triaxial arrays
EP1699479A1 (en) * 2003-12-24 2006-09-13 Leiden University Medical Center Synthetic protein as tumor-specific vaccine
WO2006116423A2 (en) 2005-04-26 2006-11-02 Eisai Co., Ltd Compositions and methods for cancer immunotherapy
US7972776B2 (en) * 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US20100003704A1 (en) * 2008-06-13 2010-01-07 Shuling Cheng IN SITU detection of early stages and late stages HPV infection
ATE518958T1 (de) 2007-01-30 2011-08-15 Transgene Sa Zur impfung verwendetes papillomavirus-e2- polypeptid
DK2224954T3 (en) 2007-11-07 2014-03-03 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
EP2427763A4 (en) 2009-05-07 2013-08-21 Oncohealth Corp IDENTIFICATION OF HIGH GRADE OR CIN2 FOR DETECTION, MONITORING AND DIAGNOSIS, AT EARLY STAGES AND ADVANCED STAGES, OF HUMAN PAPILLOMAVIRUS (HPV) AND HPV ASSOCIATED CANCERS
CN102822672B (zh) 2010-01-08 2015-12-09 安科健康公司 用于诊断和筛选与hpv有关的癌症的高通量细胞基hpv免疫测定
WO2011130434A2 (en) 2010-04-13 2011-10-20 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
WO2017184619A2 (en) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
EP3475446A1 (en) 2016-06-27 2019-05-01 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
WO2019164970A1 (en) * 2018-02-20 2019-08-29 Emory University Hpv proteins, antibodies, and uses in managing abnormal epithelial cell growth
BR112020020245A2 (pt) 2018-04-05 2021-04-06 Editas Medicine, Inc. Métodos de produzir células expressando um receptor recombinante e composições relacionadas
EP3775237A1 (en) 2018-04-05 2021-02-17 Juno Therapeutics, Inc. T cells expressing a recombinant receptor, related polynucleotides and methods
CA3108657A1 (en) 2018-08-09 2020-02-13 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
BR112021004261A2 (pt) 2018-09-11 2021-05-25 Juno Therapeutics Inc métodos para análise por espectrometria de massas de composições de células geneticamente modificadas
AU2020265741A1 (en) 2019-05-01 2021-11-25 Editas Medicine, Inc. Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
JP2023531531A (ja) 2020-06-26 2023-07-24 ジュノ セラピューティクス ゲーエムベーハー 組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
US5180806A (en) * 1988-05-16 1993-01-19 The Scripps Research Institute Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods
JPH063211B2 (ja) * 1989-03-01 1994-01-12 テイエチケー株式会社 直線摺動用ベアリング及び直線摺動用ベアリングの組付け方法
PT97073A (pt) * 1990-03-20 1991-10-31 Behringwerke Ag Processo para a preparacao de epitopos soro-reactivos de proteinas de papillomavirus 16 humano (hpv)
SE9001705D0 (sv) * 1990-05-11 1990-05-11 Medscand Ab Saett foer diagnostik av virusbaerande tumoerer genom immunoassay

Also Published As

Publication number Publication date
DE4123760C2 (de) 2000-01-20
EP0523395A2 (de) 1993-01-20
DK0523395T3 (da) 2002-02-04
AU668094B2 (en) 1996-04-26
US6723317B2 (en) 2004-04-20
CA2074153C (en) 2003-10-07
US6221577B1 (en) 2001-04-24
EP1136500A3 (de) 2004-03-24
AU2042992A (en) 1993-01-21
US6531127B2 (en) 2003-03-11
ATE206434T1 (de) 2001-10-15
PT523395E (pt) 2002-03-28
US20010034021A1 (en) 2001-10-25
EP0523395B1 (de) 2001-10-04
US20030147915A1 (en) 2003-08-07
DE59209921D1 (de) 2001-11-08
CA2074153A1 (en) 1993-01-19
EP1136500A2 (de) 2001-09-26
EP0523395A3 (es) 1994-12-14
US5601973A (en) 1997-02-11
US20040152074A1 (en) 2004-08-05
JP2003327598A (ja) 2003-11-19
JPH0867696A (ja) 1996-03-12
DE4123760A1 (de) 1993-01-21

Similar Documents

Publication Publication Date Title
ES2163394T3 (es) Regiones serorreactivas situadas en las proteinas e1 y e2 de hpv16.
EA200400241A1 (ru) Направленные к мишени мультимерные контрастные вещества, основанные на пептидах
SE9004010D0 (sv) Viralt medel
ES2138784T3 (es) Antigenos sinteticos para la deteccion de anticuerpos contra el virus de la hepatitis c.
ES2169043T3 (es) Peptidos del papilomavirus humano aplicable en las composiciones para inducir una reaccion de los linfocitos t en el hombre.
BR9814606A (pt) Formulação de vacina e métodos de tratamento de um indivìduo infectado com um vìrus hpv e de prevenção de infecção por papiloma vìrus
DE69332831D1 (de) Rekombinanter schweinepocken-virus
ES2045475T3 (es) Rna del genoma del virus de la hepatitis no-a, no-b, cdna y proteina del antigeno del virus.
ES2071815T3 (es) Analogos de delecion de los peptidos conocidos como magaininas.
MX9307465A (es) Proteinas que tienen actividad de transferasa glicosilica.
ES2145000T3 (es) Virus recombinante del avipox.
DE69322872D1 (de) Vakzine gegen immunodefizienz-virus der katze (kiv)
BR0108499A (pt) Agente terapêutico para hepatite c
BR0211186A (pt) peptìdeos e uso dos mesmos no escurecimento da pele
ES2146214T3 (es) Vacunas para actinobacillus pleuropneumoniae.
ES2153861T3 (es) Mejoras relativas a composiciones antibacterianas.
ATE189818T1 (de) Papillomavirusuntereinheit-impfstoff
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
ES2185417T3 (es) Excipientes para usar en formulaciones farmaceuticas de virus adeno-asociados, y formulaciones farmaceuticas producidas con ellos.
ES2058100T3 (es) Vacuna combinada.
ATE201693T1 (de) Hämoregulierende peptide
ES2057579T3 (es) Peptidos e1 y c de rubeola.
ES2059305T3 (es) Proteina del virus de la seudorrabia.
BR9911385A (pt) Composição, processos para dissociar um ìon de metal de uma proteìna contendo dedo de zinco, para inativar um vìrus e para selecionar um composto capaz de dissociar um ìon de metal quelado com um dedo de zinco de uma proteìna viral, vìrus isolado e inativado, kit para selecionar um composto capaz de dissociar um ìon de metal de um dedo de zinco de uma proteìna viral, composição viricida, e, formulação farmacêutica.
AR248047A1 (es) Procedimiento para la preparacion de una vacuna a base de virus del herpes bovina modificado tipo 1.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 523395

Country of ref document: ES